Dr. Melanie Saville, Head of Vaccine R&D, CEPI Vaccines:

Presentation: Vaccine development: Where are we?

Bio:

Melanie Saville joined the Coalition for Epidemic Preparedness Innovations (CEPI) in November 2017 initially as Head of Clinical development and now as Director Vaccine Development.

In her role, Melanie leads a technical team who have oversight of the CEPI funded vaccines in development. Melanie is a physician specialized in virology with 20 yrs of experience in the development and licensure of vaccines for the developed and developing world. Over the years, she has contributed to the development and licensure of several vaccines for seasonal and pandemic in uenza, pediatric combinations, Rabies, Japanese Encephalitis and Dengue vaccine in Europe, US and the international area.

Joining Wyeth in 2000 in the UK, Melanie led the phase III clinical development of a live attenuated intranasal in uenza vaccine. In addition, she contributed to several vaccine projects in early development involving adjuvants, immune modulators, viral vectors and conjugate technology.

In 2004 she joined Sano Pasteur in Lyon, France where she initially led the clinical in uenza franchise having oversight of the clinical development of several differentiated seasonal in uenza vaccine and pandemic vaccines. She then led the clinical development of a candidate dengue vaccine moving into phase III. Subsequently she became the Head of Clinical Development for a portfolio of vaccine projects managed out of the EU site. In 2013 she took on a broad role of Chief Medical and Clinical Of cer Dengue having responsibility for the clinical development and licensure of the candidate Dengue vaccine.

In 2016 she joined Janssen Vaccines and prevention in the role of Head Late Development, Clinical and Medical Affairs overseeing several vaccines in development including for Ebola, HIV, RSV and E. coli.

Prior to joining industry, Melanie worked as a clinical virologist and conducted research at the Health Protection Agency (Public Health England) in London in the eld of RSV and HSV.

Melanie obtained her medical degree from University College, London in 1993. She also obtained a Bachelor of Science in Molecular Biology from University College, London and a Masters in Medical Virology from Imperial College, London.

Dr. Melanie Saville, Head of Vaccine R&D, CEPI Vaccines:

Presentation:

Bio:

Melanie Saville joined the Coalition for Epidemic Preparedness Innovations (CEPI) in November 2017 initially as Head of Clinical development and now as Director Vaccine Development.

In her role, Melanie leads a technical team who have oversight of the CEPI funded vaccines in development. Melanie is a physician specialized in virology with 20 yrs of experience in the development and licensure of vaccines for the developed and developing world. Over the years, she has contributed to the development and licensure of several vaccines for seasonal and pandemic in uenza, pediatric combinations, Rabies, Japanese Encephalitis and Dengue vaccine in Europe, US and the international area.

Joining Wyeth in 2000 in the UK, Melanie led the phase III clinical development of a live attenuated intranasal in uenza vaccine. In addition, she contributed to several vaccine projects in early development involving adjuvants, immune modulators, viral vectors and conjugate technology.

In 2004 she joined Sano Pasteur in Lyon, France where she initially led the clinical in uenza franchise having oversight of the clinical development of several differentiated seasonal in uenza vaccine and pandemic vaccines. She then led the clinical development of a candidate dengue vaccine moving into phase III. Subsequently she became the Head of Clinical Development for a portfolio of vaccine projects managed out of the EU site. In 2013 she took on a broad role of Chief Medical and Clinical Of cer Dengue having responsibility for the clinical development and licensure of the candidate Dengue vaccine.

In 2016 she joined Janssen Vaccines and prevention in the role of Head Late Development, Clinical and Medical Affairs overseeing several vaccines in development including for Ebola, HIV, RSV and E. coli.

Prior to joining industry, Melanie worked as a clinical virologist and conducted research at the Health Protection Agency (Public Health England) in London in the eld of RSV and HSV.

Melanie obtained her medical degree from University College, London in 1993. She also obtained a Bachelor of Science in Molecular Biology from University College, London and a Masters in Medical Virology from Imperial College, London.

Prof. Arnaud Marchant, Director of the Institute for Medical Immunology, Université Libre de Bruxelles:

Presentation: Update on SARS-CoV-2 - The disease looked at by the immunologist

Prof. Arnaud Marchant, Director of the Institute for Medical Immunology, Université Libre de Bruxelles:

Presentation:

Prof. Arnaud Fontanet, Director of the Department of Global Health, Head of the Emerging Diseases Epidemiology Unit, Institut Pasteur:

Presentation Title: COVID-19 pandemic, what shall we do now?

Bio:

Professor Arnaud Fontanet is a medical epidemiologist (MD Paris V; DrPH, Harvard School of Public Health, 1993) specialized in infectious diseases epidemiology. In 2002, he joined Institut Pasteur in Paris to launch the Emerging Diseases Epidemiology unit. There, his focus has been on viral hepatitis and emerging viruses. In 2014, he was appointed as Director of the newly created Centre for Global Health at Institut Pasteur. Arnaud Fontanet is also Professor of Public Health at the Conservatoire National des Arts et Métiers, where he is Director and co-founder of the Pasteur-Cnam School of Public Health, and was named in 2018-19 Guest Public Health Professor at the Collège de France.

Prof. Arnaud Fontanet, Director of the Department of Global Health, Head of the Emerging Diseases Epidemiology Unit, Institut Pasteur:

Presentation Title:

Bio:

Professor Arnaud Fontanet is a medical epidemiologist (MD Paris V; DrPH, Harvard School of Public Health, 1993) specialized in infectious diseases epidemiology. In 2002, he joined Institut Pasteur in Paris to launch the Emerging Diseases Epidemiology unit. There, his focus has been on viral hepatitis and emerging viruses. In 2014, he was appointed as Director of the newly created Centre for Global Health at Institut Pasteur. Arnaud Fontanet is also Professor of Public Health at the Conservatoire National des Arts et Métiers, where he is Director and co-founder of the Pasteur-Cnam School of Public Health, and was named in 2018-19 Guest Public Health Professor at the Collège de France.

Prof. Bruno Lina, professor of Virology, University Claude Bernard Lyon and Director of the research laboratory VirPath:

Presentation Title: What do we know about SARS-CoV-2

Prof. Bruno Lina, professor of Virology, University Claude Bernard Lyon and Director of the research laboratory VirPath:

Presentation Title:

International Alliance for Biological Standardization


Twitter Feed

Examples of networks to address transdisciplinary issues related to infectious disease prevention and vaccine devel… https://t.co/HmhZmZFHn9
#IABS 65 conference on Infectious diseases, LYON. John Edmunds (London School of Tropical Hygiene & Medicine): Real… https://t.co/TYd0mOS3zC
Follow IABS_global on Twitter

Contact Info

IABS, Rue de la Vallée, 3
CH-1204 Geneva

Switzerland
+ 41 22 301 10 36
+ 41 22 301 10 37
This email address is being protected from spambots. You need JavaScript enabled to view it.